Enlivex Therapeutics Ltd. Net Income 2011-2026 | ENLV

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Enlivex Therapeutics Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-15 M	-29.1 M	-31.1 M	-14.5 M	-11.8 M	-9.38 M	-4.24 M	-2.5 M	-16 M	-15.4 M	-7.02 M	-1.14 M	-229 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-229 K	-31.1 M	-12.1 M

Quarterly Net Income Enlivex Therapeutics Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-3.11 M	-	-	-	-3.04 M	-	-	-	-1.46 M	-	-	-	-	-	-	-	-	-	-3.07 M	-4.67 M	-3.68 M	-4.59 M	-4.83 M	-3.55 M	-3.69 M	-3.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-1.46 M	-4.83 M	-3.55 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	-4.27 M	$ 0.82	-3.48 %	$ 4.47 M	China
Rigel Pharmaceuticals RIGL	367 M	$ 33.23	-4.03 %	$ 584 M	USA
Graybug Vision GRAY	-29.6 M	-	-11.23 %	$ 9.65 M	USA
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Acer Therapeutics ACER	-26.2 M	-	2.71 %	$ 14 M	USA
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
Apellis Pharmaceuticals APLS	22.4 M	$ 20.15	-2.68 %	$ 2.54 B	USA
AbCellera Biologics ABCL	-146 M	$ 3.72	-2.75 %	$ 1.11 B	Canada
Athersys ATHX	-87 M	-	3.77 %	$ 22.4 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
AVEO Pharmaceuticals AVEO	-53.3 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	-183 M	$ 163.7	-1.61 %	$ 8.14 B	USA
BridgeBio Pharma BBIO	-733 M	$ 64.66	-1.37 %	$ 12.4 B	USA
Brainstorm Cell Therapeutics BCLI	-11.6 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	84.9 M	-	-4.8 %	$ 255 M	USA
Burford Capital Limited BUR	172 M	$ 8.52	-2.46 %	$ 1.39 B	Britain
Adverum Biotechnologies ADVM	-131 M	-	-	$ 86.2 M	USA
CymaBay Therapeutics CBAY	-105 M	-	-	$ 3.45 B	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Avid Bioservices CDMO	-141 M	-	-	$ 789 M	USA
Certara CERT	-1.6 M	$ 7.16	1.49 %	$ 1.15 B	USA
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-20 M	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	-57.8 M	-	-	$ 2.17 B	USA
Clovis Oncology CLVS	-265 M	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Capricor Therapeutics CAPR	-22.3 M	$ 25.91	-3.56 %	$ 694 M	USA
Catalyst Pharmaceuticals CPRX	214 M	$ 24.0	0.5 %	$ 2.93 B	USA
Acasti Pharma ACST	-9.57 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	-65.3 M	$ 0.99	-3.28 %	$ 72.7 M	USA
Corvus Pharmaceuticals CRVS	-27 M	$ 17.75	-0.79 %	$ 852 M	USA
CTI BioPharma Corp. CTIC	-93 M	-	-	$ 1.2 B	USA
CohBar CWBR	-12.2 M	-	-15.44 %	$ 2.2 M	USA
Cyclacel Pharmaceuticals CYCC	-11.2 M	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	-11.2 M	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	-195 M	-	-	$ 2.18 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
Denali Therapeutics DNLI	-423 M	$ 20.02	-4.67 %	$ 3.29 B	USA
AgeX Therapeutics AGE	-14.8 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-155 M	-	-	$ 1.01 B	USA
Eton Pharmaceuticals ETON	-936 K	$ 17.54	-3.36 %	$ 450 M	USA
Entasis Therapeutics Holdings ETTX	-47.1 M	-	-	$ 105 M	USA
Evofem Biosciences EVFM	53 M	-	7.55 %	$ 38.1 M	USA